文献速递乳腺癌放疗放疗物理与技术

奥拉帕利联合同期放疗治疗炎性乳腺癌的不良事件:随机试验分析

Adverse Events in a Randomized Trial Comparing Radiation Therapy With or Without Olaparib for Inflammatory Breast Cancer.
PubMed 文献 · Int J Radiat Oncol Biol Phys · 2026-07-28

该2期随机试验纳入146例非转移性炎性乳腺癌患者,比较术后胸壁及淋巴结放疗(50 Gy联合10 Gy boost)联用或不联用奥拉帕利的不良事件。结果显示干预组3级放射性皮炎和急性胸部不良事件发生率显著更高,胃肠道及实验室异常也更常见,提示研究场景外应继续谨慎联用。

要点

  • 干预组3级放射性皮炎发生率为24.7%,对照组为5.5%(P = .003)。
  • 干预组3级急性胸部区域不良事件为24.7%,对照组为6.8%(P = .006)。
  • 干预组≥2级胃肠道不良事件及任何级别实验室异常均显著增加(均P < .001)。

核心结论

  • 研究提示在研究场景之外考虑放疗与奥拉帕利同期给药时应继续保持谨慎。

研究设计与样本

  • 2019年5月至2024年6月入组的2期NCI合作组随机试验,纳入非转移性炎性(T4d)乳腺癌患者,在新辅助系统治疗及改良根治术后随机分入对照组或干预组。
  • 对照组接受50 Gy胸壁及淋巴结放疗(含bolus)联合10 Gy boost,干预组在相同放疗方案基础上于放疗期间口服奥拉帕利25 mg每日两次。
  • 放疗期间每周按CTCAE v5.0评估不良事件,分析至放疗结束、判定为可能/很可能/肯定与治疗相关的不良事件分布,采用χ2检验比较比例。

主要发现

  • 146例可评估参与者(对照组73例,干预组73例),中位年龄54.1岁,未报告4级或5级治疗相关事件。
  • 放疗期间3级放射性皮炎在干预组为24.7%,对照组为5.5%(P = .003)。
  • 放疗期间全部急性胸部区域不良事件中,干预组3级事件为24.7%,对照组为6.8%(P = .006)。
  • 干预组1例患者在全部50 Gy照射野内出现早期融合性毛细血管扩张伴放射性苔藓样皮炎。
  • 干预组≥2级胃肠道不良事件为17.8% vs 0%(P < .001),任何级别实验室检查异常为19.2% vs 0%(P < .001)。

临床怎么用

  • 在非研究场景下,对炎性乳腺癌患者同期使用放疗与奥拉帕利应保持谨慎,并加强放射性皮炎及胸部区域急性不良事件的监测。
  • 同期治疗期间需关注胃肠道不良事件及实验室检查异常,干预组≥2级胃肠道事件和任何级别实验室异常均显著高于对照组。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: Recent conflicting reports regarding the tolerability of poly (ADP-ribose) polymerase (PARP) inhibitors administered concurrently with breast radiation therapy motivate analysis of adverse events reported in a large national cooperative group trial. METHODS AND MATERIALS: From May 2019 to June 2024, we enrolled patients with inflammatory (T4d) nonmetastatic breast cancer to a phase 2 NCI-cooperative group trial, which randomized patients after neoadjuvant systemic therapy selected by the treating physician and modified radical mastectomy to 2 arms. The control arm was assigned 50 Gy of chest wall and nodal radiation therapy, including bolus, plus 10-Gy boost. The intervention arm was assigned the same radiotherapeutic regimen with 25 mg of olaparib twice daily during radiation therapy. Adverse events were assessed using the Common Terminology Criteria for Adverse Events v5.0 weekly during radiation therapy. This analysis explores the distribution of radiation dermatitis, all acute adverse events in the chest-wall region, and other adverse events through the end of radiation therapy by study arm, where the adverse events were deemed possibly, probably, or definitely treatment-related. χ2 tests were used to compare proportions. RESULTS: Among 146 evaluable participants (73 control, 73 intervention), median age was 54.1. No grade 4 or 5 treatment-related events were reported. Grade 3 radiation dermatitis was reported in 24.7% of patients in the intervention arm and 5.5% in the control arm (P = .003) during radiation therapy. When considering all acute chest-region adverse events, 24.7% had grade 3 acute adverse events in the intervention arm versus 6.8% in the control arm (P = .006) during treatment. One patient on the intervention arm had early, confluent telangiectasia throughout the 50-Gy fields with radiation-induced lichenoid dermatitis. Intervention arm patients were more likely to experience grade 2 or greater gastrointestinal adverse events (17.8% vs 0%, P < .001) and any grade of laboratory investigation abnormalities (19.2% vs 0%, P < .001). CONCLUSIONS: This analysis suggests continued caution if considering concurrent administration of radiation therapy and olaparib outside of the investigational context.

来源:Int J Radiat Oncol Biol Phys,查看原文。版权归原作者所有。

引用

  1. Jagsi R, Meisner A, Chalasani P, et al. Adverse Events in a Randomized Trial Comparing Radiation Therapy With or Without Olaparib for Inflammatory Breast Cancer. Int J Radiat Oncol Biol Phys. 2026. PMID: 42520859. doi:10.1016/j.ijrobp.2026.07.029

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。